A clinical dossier on the Merck Animal Health (MSD) veterinary portfolio: global Nobivac vaccines, Bravecto fluralaner safety profile, and Allflex livestock diagnostics.

What does the public data reveal about the Merck Animal Health (MSD Animal Health) veterinary portfolio, and what should a veterinary clinic owner, practice manager, regulatory affairs specialist, or food-animal veterinarian do with it?

Merck Animal Health—known as MSD Animal Health outside the United States and Canada—is one of the dominant global giants in veterinary pharmaceuticals, biologics, and digital tracking technology. Following a legacy of major consolidations, including the integration of Intervet and Schering-Plough Animal Health, Merck has built a portfolio that is highly influential in both companion animal practices and commercial livestock operations. For clinical decision-makers and practice operators, Merck's products are both essential clinical tools (such as the Nobivac vaccine line and Vetsulin) and high-volume revenue drivers (such as the Bravecto parasiticide family).

However, managing a Merck-heavy inventory requires a detailed understanding of the regulatory profile, active substance pathways, and real-world safety records of these compounds. This dossier analyzes the Merck Animal Health portfolio using official regulatory records from the European Medicines Agency (EMA) centralized authorization registry, the USDA APHIS Center for Veterinary Biologics, and the United States Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM), combined with aggregated post-market pharmacovigilance data from the FDA CVM public adverse-event database.

Fast Answer

What is the therapeutic scope of the Merck Animal Health (MSD) portfolio, and what does safety data reveal about fluralaner?

The Merck Animal Health (MSD) portfolio spans four primary operational pillars: pharmaceuticals, vaccines (biologics), digital herd intelligence (Allflex), and aquaculture. Key brands include Bravecto (fluralaner), Vetsulin/Caninsulin (porcine insulin zinc suspension), and the Nobivac vaccine family.

An analysis of the FDA CVM public adverse-event database (a public extract dated June 2026 containing roughly 1.34 million reports) shows that fluralaner (Bravecto) — Merck's signature companion-animal active ingredient and an essentially single-source Merck product — accounts for 86,055 reports, of which 43,814 (50.9%) carry a serious adverse-event flag. Roughly 64,000 of those reports involve dogs and 13,000 involve cats. This fluralaner signal dwarfs Merck's other companion-animal actives: porcine insulin zinc (Vetsulin) and fenbendazole (Panacur) add only a few thousand further reports between them, and because both are older, multi-manufacturer active ingredients, those counts are not uniquely Merck. Across the three actives combined and de-duplicated by unique report ID, the database holds 90,292 reports.

At the same time, the European Medicines Agency (EMA) Union Register returns 18 centralized veterinary records under Merck's European entity (Intervet International BV) — though the status matters more than the raw count: 4 next-generation Nobivac NXT recombinant feline vaccines sit at CVMP opinion/evaluation status (Merck's clearest EU pipeline signal), while most of the older centralized authorizations (e.g., Nobivac Myxo-RHD, Bovilis BTV8, Porcilis Pesti) have been withdrawn or lapsed.

These adverse-event figures represent passive surveillance and do not indicate direct incidence rates or establish causation, as the total denominator of treated animals is not public. However, they establish clear risk boundaries. For veterinary practitioners, the data demonstrates that while fluralaner provides highly effective 12-week flea and tick control, clinicians must perform a thorough neurological pre-screening and implement structured client communication regarding the potential for transient tremors, ataxia, or seizures associated with the isoxazoline class.

What are the core therapeutic categories in the Merck Animal Health portfolio?

Merck's global footprint is divided into companion animal and livestock segments. The portfolio's clinical application can be mapped across four primary categories:

                  ┌──────────────────────────────────────────┐
                  │    Merck Animal Health (MSD) Portfolio   │
                  └────────────────────┬─────────────────────┘
                                       │
         ┌───────────────┬─────────────┼───────────────┬───────────────┐
         ▼               ▼             ▼               ▼               ▼
    Parasiticides    Biologicals  Endocrine/Rx    Digital Tech    Aquaculture
     (Bravecto)       (Nobivac)    (Vetsulin)      (Allflex)     (Slice/Aqua)

1. Parasiticides (Companion Animal)

The parasiticide category is dominated by the Bravecto (fluralaner) family. Fluralaner is a systemic insecticide and acaricide belonging to the isoxazoline class. It acts as an antagonist at ligand-gated chloride channels (specifically GABA and glutamate receptors) in the insect nervous system.

Bravecto Chew: Dosed once every 12 weeks (with an 8-week exception for certain tick species like Amblyomma americanum in the US). It represents a major compliance advantage over monthly oral tick preventives.
Bravecto Spot-On: A topical formulation for dogs and cats, particularly useful for feline patients where oral administration is challenging.
Bravecto Plus: A feline topical combination of fluralaner and moxidectin (a macrocyclic lactone), expanding the coverage to heartworms, roundworms, hookworms, and ear mites.

2. Biologicals (Vaccines)

Merck is a world leader in veterinary biologics, operating under the Nobivac brand for companion animals and various Porcilis and Bovilis brands for swine and cattle.

Companion Animal (Nobivac): Includes core canine vaccines (Nobivac DAPPv, Rabies) and specialized non-core vaccines like Nobivac Lyme (an inactivated borrelia vaccine containing outer surface protein A [OspA] to block transmission inside the tick midgut) and Nobivac Canine Flu H3N8/H3N2. The feline line covers FVRCP and leukemia (Nobivac FeLV).
MSD European Recombinants: Under the EMA register, Merck has pioneered vector vaccines (like Nobivac Myxo-RHD for rabbits) and next-generation purification methods, reducing local injection site reactions.
Livestock Biologics: Includes vaccines targeting Bovine Respiratory Disease (BRD), Porcine Reproductive and Respiratory Syndrome (PRRS), and poultry pathogens (Vectormune).

Vaccine Handling and Cold-Chain Integrity

A Nobivac (or any modified-live) vaccine is only as good as the cold chain that delivered it. Modified-live vaccines are especially fragile: a single temperature excursion can attenuate titer to the point of clinical failure even though the vial looks normal. Practices running Merck biologics should maintain a logged refrigerator (2–8 °C, never frozen), respond to any excursion with a documented assessment, and never use product whose storage history is uncertain. The clinic-level discipline for this — monitoring, excursion response, and discard rules — is covered in our vaccine refrigerator temperature excursion protocol. Mishandled biologics are a leading non-obvious cause of "vaccine failure" and outbreaks in otherwise well-vaccinated populations.

Companion-Animal Core Vaccine Schedule (Reference)

For practices standardizing on Nobivac, the AAHA/WSAVA-aligned core framework is the reliable anchor; non-core products (Lyme, leptospirosis, influenza, Bordetella) are layered on risk. Canine core (DAPP and rabies) follows the puppy series → one-year booster → triennial adult pattern, with rabies on its labeled schedule (typically one year then triennial, per the product license and local law). Feline core (FVRCP and rabies) follows an analogous kitten series → booster → adult cycle. Two operating principles matter regardless of brand: (1) the final puppy/kitten dose should be given at ~16 weeks to minimize maternal-antibody interference, and (2) annual vs triennial adult scheduling follows the specific product's licensed duration — a Nobivac label claim of three-year duration is not transferable to a different brand labeled for one year. Always follow the specific product insert and current AAHA/AAFP guidance.

3. Endocrine & Specialty Pharmaceuticals

Merck maintains several classic prescription drugs that serve as standard-of-care options for chronic companion animal diseases:

Vetsulin (Caninsulin outside the US): An aqueous suspension of porcine insulin zinc (consisting of 35% amorphous and 65% crystalline insulin). Because porcine insulin shares an identical amino acid sequence with canine insulin, it is the primary FDA-approved insulin for dogs (and is also approved for cats).
Panacur (Fenbendazole): A classic benzimidazole anthelmintic that binds to tubulin in helminths, disrupting microtubule structure and energy metabolism. It is widely used in multiple species (dogs, cats, livestock, horses) for nematodes, hookworms, whipworms, and tapeworms.

4. Animal Health Intelligence (Digital Technology)

Following the strategic acquisition of Antelliq (parent of Allflex), Merck has integrated digital monitoring into veterinary herd management:

Allflex SenseHub: Utilizes smart ear tags and collars to monitor rumination, activity, and heat cycles in dairy and beef cattle.
ezyVet / PIMS Connectivity: While Allflex primarily integrates with herd management software (like DairyComp 305), Merck's companion animal operations have increasingly focused on connecting diagnostic pipelines with practice information systems.

Isoxazoline Comparison: Fluralaner vs. Competitor Molecules

To assist clinical directors in product selection, the table below compares Merck's fluralaner against competitor molecules in the isoxazoline class (sarolaner, afoxolaner, lotilaner).

Feature	Fluralaner (Bravecto - Merck)	Sarolaner (Simparica - Zoetis)	Afoxolaner (NexGard - BI)	Lotilaner (Credelio - Elanco)
Dosing Frequency	Every 12 Weeks (with minor exceptions)	Monthly (Every 30 Days)	Monthly (Every 30 Days)	Monthly (Every 30 Days)
Administration Route	Oral (chew) or Topical (spot-on)	Oral (chew)	Oral (chew)	Oral (chew)
Minimum Age / Weight	6 months / 4.4 lbs (Chew); 6 months / 2.6 lbs (Cat Spot-On)	6 months / 2.8 lbs	8 weeks / 4.0 lbs	8 weeks / 4.4 lbs (Dog); 8 weeks / 2.0 lbs (Cat)
Feline Formulation	Yes (Topical Spot-on)	No (Only as combination Revolution Plus)	No (Only as combination NexGard Combo)	Yes (Oral Chew)
Elimination Half-life	Long (~12 to 15 days in dogs), enabling extended dosing.	Intermediate (~11 to 12 days in dogs).	Short (~14 days, but cleared rapidly via feces).	Short (~8 days).
Neurological Cautions	Class warning for ataxia, tremors, and seizures.	Class warning for ataxia, tremors, and seizures.	Class warning for ataxia, tremors, and seizures.	Class warning for ataxia, tremors, and seizures.
Food Requirement	Must be administered with food to maximize absorption.	Can be administered with or without food.	Can be administered with or without food.	Must be administered with food or within 30 min of feeding.

Analyzing openFDA Adverse Event Reports for Merck Active Substances

An evaluation of the public safety database maintained by the FDA CVM (June 2026 extract) reveals distinct reporting profiles for Merck's signature active substances.

As a critical baseline, adverse event reports represent passive surveillance data. These numbers reflect complaints submitted by veterinarians and pet owners. They do not represent incidence rates (the total number of treated animals is not public) and do not prove the drug caused the event. They show reporting volume and severity profiles.

Across Merck's three companion-animal actives combined and de-duplicated by unique report ID, the database holds 90,292 reports, of which 44,420 (49.2%) carry a serious adverse-event flag. The reporting volume is overwhelmingly driven by fluralaner (Bravecto), which alone accounts for 86,055 reports (43,814 serious, 50.9%).

Merck Ingredient Performance Matrix

Active Ingredient (Brand Name)	Total Reports	Serious Adverse Events	Serious AE %	Top Reported Clinical Signs
Fluralaner (Bravecto)	86,055	43,814	50.9%	Vomiting, diarrhea, lethargy, anorexia, seizures, ataxia, tremors.
Porcine Insulin Zinc (Vetsulin)	57	26	45.6%	Hypoglycemia, lack of efficacy, lethargy, vomiting.
Fenbendazole (Panacur)	4,207	590	14.0%	Vomiting, diarrhea, lethargy, anorexia.

Report counts are matched on active_ingredient (brand names are masked in the public file) and de-duplicated by unique report ID. Porcine insulin zinc and fenbendazole are sold by several manufacturers, so those two rows are not Merck-exclusive; fluralaner, by contrast, is essentially a single-source Merck active ingredient, so its count is a clean Merck signal.

Fluralaner Safety Profile and Neurological Risk Boundaries

The 50.9% serious-flag rate for fluralaner in the database is prominent. In 2018, the FDA issued a class-wide communication warning pet owners and veterinarians about potential neurologic adverse events associated with isoxazoline class drugs. This warning was based on reports of muscle tremors, ataxia, and seizures across the entire class, including fluralaner.

When analyzing the fluralaner reports:

Extended Exposure Window: Unlike monthly products, fluralaner remains in the animal's tissues for 12 weeks. If an adverse event occurs, the drug cannot be cleared rapidly, which can extend the duration of supportive care.
Neurological Signs: Tremors, ataxia, and seizures are reported in a small subset of patients. Clinicians should avoid prescribing fluralaner (or any isoxazoline) to dogs with a history of epilepsy or seizure disorders. For the full label-based and post-marketing breakdown of these signs, see our dedicated Bravecto side effects in dogs analysis.
Vomiting and Diarrhea: The most common reactions are transient gastrointestinal upset. Dosing with food, as labeled, reduces the risk of gastrointestinal irritation and ensures bio-availability.

Fluralaner Decision Rules and Failure Cases

The reporting volume around fluralaner is not, by itself, a reason to avoid Bravecto — it is a reason to prescribe it deliberately. Concrete rules that keep the 12-week duration an advantage rather than a liability:

Screen before the first dose. Take a brief seizure/neurological history. A dog with epilepsy, prior post-vaccine tremors, or an unknown neurologic background is a candidate for a monthly isoxazoline or a non-isoxazoline class rather than a 12-week-commitment molecule.
Interpret a "lack of efficacy" report correctly. A meaningful share of fluralaner reports are fleas or ticks still present after a dose — i.e., reported preventive failure, not a side effect. Before switching products, confirm the dose was appropriate for weight, given with food (which doubles absorption), and that environmental flea burden (immature life stages in the home) is being addressed. Persistent true failure should feed into parasite preventive failure surveillance and resistance monitoring rather than an assumption the drug is "weak."
If a neurologic reaction occurs, act on the long half-life. Unlike a monthly product that clears in days, fluralaner persists. There is no antidote; management is supportive (control seizures, manage tremors, maintain hydration) and the animal may need monitoring for an extended window. Document the event and avoid re-dosing the isoxazoline class in that patient.
Feline route matters. For cats, the topical spot-on (fluralaner, or fluralaner + moxidectin as Bravecto Plus) is the standard route; oral isoxazoline tolerance differs by species and product. Do not transfer a canine oral isoxazoline protocol to a cat.

What does the EMA data reveal about Merck's European biologics pipeline?

The European Medicines Agency (EMA) Union Register of veterinary medicinal products provides a detailed view of Merck's (registered under Intervet International BV) European operations. Centralized authorizations are valid across all EU Member States, but the register's picture for Merck is more about a renewed feline-vaccine pipeline and a long tail of lapsed older authorizations than a broad active portfolio.

A query of the EMA Union Register (extract dated June 2026) returns 18 centralized veterinary records under Intervet International BV — but the status of those records is the important part: none are currently in plain "Authorised" status. The breakdown:

4 next-generation recombinant feline vaccines (Nobivac NXT platform) sit at CVMP opinion / evaluation status on the centralized route — the clearest signal of where Merck is investing in Europe:
1. Nobivac NXT HC — feline herpesvirus-based recombinant vector vaccine.
2. Nobivac NXT HCP — adds calicivirus protection to the recombinant vector platform.
3. Nobivac NXT HCPCh — extends coverage to Chlamydia felis.
4. Nobivac NXT HCPChFeLV — adds feline leukemia virus (FeLV) coverage. These recombinant vector vaccines are designed to express protective antigens with minimal adjuvant, reducing injection-site inflammation — a meaningful advance over older inactivated feline vaccines.
13 records are Withdrawn (e.g., Nobivac Myxo-RHD recombinant rabbit myxomatosis/RHD vaccine, Bovilis BTV8 bluetongue serotype-8 vaccine, Porcilis Pesti classical swine fever marker vaccine, Activyl Tick Plus [indoxacarb/permethrin], Nobivac Piro babesiosis vaccine, Zubrin [tepoxalin], Ibaflin [ibafloxacin], and several Nobilis poultry influenza vaccines), plus 1 application withdrawn (Equilis EHV 1+4, equine herpesvirus vaccine). In the EU, "Withdrawn" central status usually reflects commercial discontinuation or a move to national authorizations rather than a safety action; readers should not infer the products were pulled for harm.

The practical read for a clinic or regulatory team is that Merck/MSD's active European presence leans heavily on nationally authorized companion-animal products (Nobivac dog and cat vaccines, Bravecto) plus the newer Nobivac NXT centralized pipeline, while many older centralized authorizations have lapsed. Always confirm a specific product's current authorization status in the EMA Union Register or the relevant national authority before relying on it.

Antimicrobial Stewardship Note

Several Merck/MSD antimicrobials are subject to evolving European restrictions on critically important human antimicrobials. Veterinary managers must monitor these registrations as European guidelines continue to restrict third- and fourth-generation cephalosporins (e.g., cefquinome) and certain macrolides/fluoroquinolones in livestock.

Vetsulin (Porcine Insulin Zinc) Protocol and Species Specifics

Vetsulin is a key endocrine asset in Merck's portfolio. It is classified as an intermediate-acting insulin. Understanding its pharmacokinetics is essential for successful diabetes mellitus management in dogs and cats:

        ┌────────────────────────────────────────────────────────┐
        │            Vetsulin Dosing & Monitoring Flow           │
        └───────────────────────────┬────────────────────────────┘
                                    │
                       Perform Diagnostic Baseline
                     (Fructosamine & Urine Analysis)
                                    │
                            Initiate Vetsulin
                  (0.5 U/kg QD Dogs; 1-2 U/cat BID Cats)
                                    │
                     ┌──────────────┴──────────────┐
                     ▼                             ▼
              Day 7-10 Recheck              Day 7-10 Recheck
             (12-Hour Blood Curve)          (In-Home Monitoring)
                     │                             │
                     └──────────────┬──────────────┘
                                    │
                                    ▼
                       Adjust Dose in 10-25% Steps
                     (Target Nadir: 100-150 mg/dL)

1. Species Approvals & Formulations

Porcine Origin: Vetsulin is structured as a porcine insulin zinc suspension. Porcine insulin has the exact same amino acid sequence as canine insulin. This minimizes the risk of anti-insulin antibody formation in dogs, which can occur with recombinant human or bovine insulin formulations.
Concentration (U-40): Vetsulin is formulated at 40 IU/mL. This is critical. Standard human insulins are formulated at 100 IU/mL (U-100). Using a U-100 syringe with U-40 insulin will result in a severe underdose (2.5 times less insulin than intended), while using U-40 syringes with U-100 insulin will result in a fatal overdose. Clinics must verify that clients receive the correct U-40 syringes and clearly counsel them on this distinction.

2. Clinical Dosing Logic

Dogs: The labeled starting dose is 0.5 IU/kg given subcutaneously once daily, with or immediately after a meal. Twice-daily dosing is added only if the duration of insulin action is inadequate; when BID dosing is initiated, each dose should be roughly 25% lower than the once-daily dose that produced an acceptable nadir. (The AAHA Diabetes Management guideline similarly starts most dogs at 0.25–0.5 U/kg BID — consistent with the BID-reduced-dose logic.) Always follow the current product label and the prescribing veterinarian.
Cats: The starting dose is 1 to 2 IU per cat BID. Cats metabolize insulin more rapidly than dogs; while some cats can be managed once daily, BID dosing is required in the vast majority of feline patients to maintain glycemic control.
Monitoring: Clinicians must perform a 12-hour blood glucose curve 7 to 10 days after starting therapy or making a dose adjustment. The nadir (lowest glucose point) should occur approximately 6 to 8 hours post-injection, targeting a range of 100–150 mg/dL (5.5–8.3 mmol/L) in dogs and 100–180 mg/dL in cats.

Vetsulin Failure Cases and Troubleshooting

When a diabetic dog or cat is "not responding" to Vetsulin, three patterns account for most cases, and each has a different fix:

The Somogyi (rebound) curve: An overly aggressive dose drives glucose below the nadir, triggering a counter-regulatory surge that produces fasting hyperglycolaemia — the patient looks "under-dosed" but is actually over-dosed. The curve shows a sharp dip followed by a steep rebound. The fix is a dose reduction, not an increase; escalating into a Somogyi loop is a classic mistake that cycles the patient through repeated hypoglycemia.
Duration failure (the label reason to go BID): If the once-daily Vetsulin dose produces an acceptable nadir but glucose climbs back above target well before 24 hours, duration of action is inadequate — the labeled trigger to split to twice-daily dosing at ~25%-reduced doses. This is normal canine physiology, not product failure.
Hypoglycemia recognition: Lethargy, shaking, stumbling, seizures, or collapse in a Vetsulin-treated patient is hypoglycemia until proven otherwise. Owners must be coached to recognize early signs, keep a glucose source (corn syrup/karo syrup) on hand, and present immediately. Hypoglycemia, anorexia (missed meals dosed as if eaten), and seizures are exactly what dominate the porcine insulin zinc openFDA reports — they reflect real-world dosing and feeding mismatches more than intrinsic drug toxicity.
When to switch insulins: In cats, glargine achieves higher diabetic remission rates than intermediate-acting insulins in several trials; a cat that is persistently poorly controlled on Vetsulin despite correct dosing and curve-based adjustments is a candidate to switch. In dogs that remain unstable, re-evaluate for concurrent disease (Cushing's, infection) before blaming the insulin.

Allflex Herd Monitoring Systems: Practice Workflow Integration

Merck's digital portfolio, managed under Allflex Livestock Intelligence, represents a shift toward predictive veterinary medicine. In large-scale dairy and beef operations, Allflex integration directly alters the herd health workflow:

1. The Technology Stack

SenseHub Collars and Ear Tags: These sensors monitor rumination, eating, active behavior, and resting time.
Heatime Pro+ Console: A local and cloud-based console that processes sensor data to generate actionable alerts.

2. Integration with Practice Workflows

Automated Heat Detection: Eliminates the need for manual tail-chalking or visual heat observation, reducing labor costs and improving conception rates.
Early Health Alerts: The system detects drops in rumination time up to 24 hours before clinical signs of disease (such as mastitis, ketosis, or displaced abomasum) appear. This allows the herd veterinarian to intervene early, reducing treatment costs and antibiotic use.
PIMS Integration: Herd health data from SenseHub syncs with herd management software (e.g., DairyComp 305 or VAS). This ensures that cow health histories, diagnostic results, and treatment logs are consolidated without manual entry.

Allflex ROI and Implementation Failure Cases

SenseHub and similar monitoring systems pay for themselves only when the herd veterinarian acts on the alerts; the technology is the easy part, the workflow change is the hard part. Common failure modes:

Alert fatigue. A system tuned too sensitively generates more health alerts than staff can investigate, and the herd eventually ignores them — at which point the early-warning value (a rumination drop 24 hours before clinical mastitis or ketosis) is lost. Alert thresholds must be calibrated to the farm's labor capacity, not left at factory defaults.
Tag application and retention losses. Ear-tag sensors are only useful while they are attached and reporting. Poor application technique, tag loss, or dead batteries create "dark" animals whose health events the system cannot see. A periodic tag-attachment and battery-health audit is part of operating the system, not an optional maintenance task.
Acting on heat but not health. Many farms adopt Allflex primarily for automated heat detection (conception-rate gains) and underuse the health-alert side. The health-alert module is where the veterinary value sits — early intervention that reduces antibiotic use, treatment cost, and cull rate — and a herd-health program that ignores those alerts leaves most of the ROI on the table.
Integration that is read-only. If SenseHub data flows into DairyComp but treatment records do not flow back, the herd veterinarian is working from a one-way picture. Bidirectional sync (alerts → worklists → recorded treatments → outcome tracking) is what turns monitoring data into a managed health program.

FAQ: Common Clinical Questions

How does Vetsulin compare to human insulin glargine (Lantus) in cats?

Vetsulin is an intermediate-acting porcine insulin zinc suspension, whereas glargine is a long-acting peakless human insulin analogue. In feline patients, glargine has been shown in multiple clinical trials to achieve higher rates of diabetic remission compared to intermediate-acting insulins. Because cats have a high rate of glucose clearance and variable metabolism, the long, flat action profile of glargine is often more effective at maintaining stable glycemic levels. However, Vetsulin remains a reliable option and is specifically approved for veterinary use, whereas glargine is used off-label in veterinary medicine.

What are the clinical signs of a Bravecto overdose?

In safety studies, Bravecto (fluralaner) was administered to puppies at up to 5 times the maximum labeled dose of 56 mg/kg at 8-week intervals for three treatments. No treatment-related adverse effects were observed. In cats, topical fluralaner was tolerated at up to 5 times the maximum dose with no systemic signs. If an accidental overdose occurs in a dog with a pre-existing MDR1 mutation or a seizure history, clinicians should monitor for neurological signs (ataxia, tremors, salivation, seizures) and implement supportive care, as there is no specific reversing agent for isoxazolines.

Can Nobivac Lyme vaccine be administered to cats?

No. Nobivac Lyme is licensed by the USDA CVB exclusively for use in dogs. Lyme disease (Borrelia burgdorferi infection) is highly clinical in dogs, causing shifting leg lameness, arthritis, and glomerulonephritis. In contrast, cats are naturally resistant to Lyme disease and rarely show clinical signs, meaning there is no clinical indication or approved vaccine for feline Borreliosis.

How does Allflex technology communicate with a clinic's database?

Allflex SenseHub controllers transmit data wirelessly via radio frequency (RF) to an on-farm antenna. This antenna connects to the internet via Ethernet or cellular link, forwarding the data to the SenseHub cloud database. Herd managers and visiting veterinarians access this data via mobile apps or desktop interfaces. Standard integrations allow this data to flow bi-directionally with popular dairy management databases, reducing duplicate entries for calving dates, disease diagnoses, and cull events.

How does Vetsulin's U-40 concentration create dosing risk?

Vetsulin is formulated at 40 IU/mL (U-40), whereas most human insulins are 100 IU/mL (U-100). The hazard is syringe mismatch: drawing U-40 insulin to the "10-unit" mark on a U-100 syringe delivers only ~4 IU (a 2.5-fold underdose), while drawing U-100 insulin into a U-40 syringe to the same mark delivers ~25 IU (a potentially fatal overdose). Clinics dispensing Vetsulin must dispense matching U-40 syringes and explicitly coach owners never to substitute a household U-100 insulin syringe. Dedicated U-40 insulin pens (dosing in 0.5 or 1 IU increments) reduce this error and are available for dogs and cats where precise small doses matter.

Is there a generic or interchangeable version of Bravecto?

No fluralaner product other than Merck's Bravecto family is approved in the U.S.; fluralaner is, for practical purposes, a single-source Merck active ingredient. Several other isoxazolines (afoxolaner, sarolaner, lotilaner) from competing manufacturers provide the same drug class with monthly (rather than 12-week) dosing, and some have generic equivalents. A clinic seeking a lower-cost isoxazoline should substitute within the class to a competitor molecule with a generic option — not assume a "generic Bravecto" exists. The 12-week duration is currently unique to fluralaner and is the main reason a practice tolerates its higher per-dose cost for compliant owners.

What is the practical difference between Bravecto Chew and Bravecto topical for cats?

For dogs, the oral chew is the default and must be given with food to maximize absorption. For cats — where oral administration is often impractical — the Bravecto topical spot-on delivers fluralaner transdermally and avoids the pilling battle. Bravecto Plus (feline topical) combines fluralaner with moxidectin to extend coverage to heartworm prevention and treatment of roundworms, hookworms, and ear mites in a single spot-on, which is a meaningful compliance advantage for feline parasite control. The choice between chew and topical is therefore species- and owner-driven: oral for most dogs, topical combination for cats and for dogs that cannot be reliably pilled. Always confirm the specific product's labeled minimum age and weight, and recheck the current label, as feline isoxazoline labeling has expanded over time.

What is the withdrawal period for Panacur (fenbendazole) in food animals?

Fenbendazole withdrawal times vary by species, dose, and formulation, so the specific product label must always be checked. In US cattle, Panacur/Safe-Guard Suspension 10% and paste carry an 8-day slaughter withdrawal; the milk discard depends on the presentation — the current 10% suspension label specifies a 48-hour milk discard, while some 5 mg/kg paste and suspension approvals (per FDA Freedom of Information summaries) carry a zero-hour milk discard at the labeled 5 mg/kg dose. Notably, the 10 mg/kg dose used for Type II ostertagiasis or tapeworms in beef cattle is not cleared for use in dairy cattle because of residue concerns. In swine, fenbendazole feed and oral withdrawal times fall roughly in the 3- to 15-day range depending on the product. Clinicians and producers must always verify the exact product label and country-specific regulations to prevent drug residues in the food supply.

Sources

European Medicines Agency Union Register of Veterinary Medicinal Products: Centralized Authorizations for Intervet International BV. https://ec.europa.eu/health/documents/community-register/html/index_en.htm
FDA Center for Veterinary Medicine (CVM) Approved Animal Drug Database: New Animal Drug Applications (NADA) for fluralaner, porcine insulin zinc suspension, and fenbendazole. https://www.fda.gov/about-fda/center-veterinary-medicine
FDA CVM Drug Adverse Event Registry: Aggregated Pharmacovigilance Reports for fluralaner, porcine insulin zinc, and fenbendazole (records processed through June 2026). https://www.fda.gov/animal-veterinary/safety-reports/adverse-drug-experience-reports
USDA Animal and Plant Health Inspection Service (APHIS) Center for Veterinary Biologics Product Summaries. https://www.aphis.usda.gov/veterinary-biologics/product-summaries
Allflex Livestock Intelligence Technical Support & Software Integration Documentation. https://www.allflex.global/

Vet Med Guide

Merck Animal Health Veterinary Portfolio: Vaccines, Bravecto, and Monitoring Systems